Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
XRP Treasury Giant Delays Nasdaq Debut

XRP Treasury Giant Delays Nasdaq Debut

BeInCryptoBeInCrypto2026/10/07 07:54
Evernorth Holdings, the Ripple-backed company building the largest publicly traded pure-play XRP treasury, delayed its expected Nasdaq debut because of an administrative issue disclosed on October 6. The new date is now October 12, and XRPs price barely reacted to this news. Evernorths Nasdaq Listing Timeline After the Delay Evernorth is going public on Nasdaq through a merger with Armada Acquisition Corp. II, under the ticker XRPN. Once listed, investors can buy its shares on a regulated exchange. The company expects the combined shares to start trading on Monday, October 12, pending closing conditions and Nasdaq listing requirements. The original plan targeted a close on October 7 and a debut on October 8. Due to an administrative delay that is not expected to affect the closing, we now expect to close on Friday, October 9th, with XRPN expected to start trading on Nasdaq on Monday, October 12th, in each case subject to customary closing conditions and Nasdaq listing requirements. Evernorth said the delay is purely administrative and not expected to affect the closing. Armada II shareholders already approved the merger on September 30. At closing, Evernorth expects to hold about 473 million XRP, plus roughly $300 million in gross cash proceeds. That would make it the largest publicly traded pure-play XRP treasury company. Will the Delay Affect XRP Price? XRP price fell nearly 2% today, largely driven by a liquidity flush that affected the whole market. However, the altcoins fundamental indicators remain largely bullish. XRP ETFs recently recorded 12 straight weeks of inflow. Market analysts note that the listing itself does not create new buying pressure for XRP. Investors and partners contributed most of the treasury before the public debut. In other words, the XRP backing the company already exists, so the listing creates no new demand for the token. The market took the short delay calmly. In the longer term, a successful XRPN launch could still help XRP. It would give traditional investors a regulated equity vehicle focused on growing XRP holdings per share through active treasury management. That access may widen the buyer base over time, although analysts see no immediate price effect.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court

October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)

路透社•2026/10/07 13:31

BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises

On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.

路透社•2026/10/07 13:27

Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.

Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.

智通财经•2026/10/07 13:18